- Previous Close
2.7500 - Open
2.6700 - Bid 2.5000 x 100
- Ask 2.7000 x 100
- Day's Range
2.5500 - 2.7100 - 52 Week Range
2.4500 - 6.4800 - Volume
65,113 - Avg. Volume
99,077 - Market Cap (intraday)
45.418M - Beta (5Y Monthly) 1.38
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2700 - Earnings Date May 6, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.50
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
www.envveno.comRecent News: NVNO
View More
Performance Overview: NVNO
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVNO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVNO
View MoreValuation Measures
Market Cap
48.22M
Enterprise Value
6.13M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.14
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.82%
Return on Equity (ttm)
-49.39%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-21.82M
Diluted EPS (ttm)
-1.2700
Balance Sheet and Cash Flow
Total Cash (mrq)
43.15M
Total Debt/Equity (mrq)
2.52%
Levered Free Cash Flow (ttm)
-9.67M
Research Analysis: NVNO
View MoreResearch Reports: NVNO
View MoreDaily – Vickers Top Insider Picks for 03/14/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/13/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/12/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/11/2025
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.